Literature DB >> 15374952

Functional characterization of the candidate tumor suppressor gene NPRL2/G21 located in 3p21.3C.

Jingfeng Li1, Fuli Wang, Klas Haraldson, Alexey Protopopov, Fuh-Mei Duh, Laura Geil, Igor Kuzmin, John D Minna, Eric Stanbridge, Eleonora Braga, Vladimir I Kashuba, George Klein, Michael I Lerman, Eugene R Zabarovsky.   

Abstract

Initial analysis identified the NPRL2/G21 gene located in 3p21.3C, the lung cancer region, as a strong candidate tumor suppressor gene. Here we provide additional evidence of the tumor suppressor function of NPRL2/G21. The gene has highly conserved homologs/orthologs ranging from yeast to humans. The yeast ortholog, NPR2, shows three highly conserved regions with 32 to 36% identity over the whole length. By sequence analysis, the main product of NPRL2/G21 encodes a soluble protein that has a bipartite nuclear localization signal, a protein-binding domain, similarity to the MutS core domain, and a newly identified nitrogen permease regulator 2 domain with unknown function. The gene is highly expressed in many tissues. We report inactivating mutations in a variety of tumors and cancer cell lines, growth suppression of tumor cells with tet-controlled NPRL2/G21 transgenes on plastic Petri dishes, and suppression of tumor formation in SCID mice. Screening of 7 renal, 5 lung, and 7 cervical carcinoma cell lines showed homozygous deletions in the 3' end of NPRL2 in 2 renal, 3 lung, and 1 cervical (HeLa) cell line. Deletions in the 3' part of NPRL2 could result in improper splicing, leading to the loss of the 1.8 kb functional NPRL2 mRNA. We speculate that the NPRL2/G21 nuclear protein may be involved in mismatch repair, cell cycle checkpoint signaling, and activation of apoptotic pathway(s). The yeast NPR2 was shown to be a target of cisplatin, suggesting that the human NPRL2/G21 may play a similar role. At least two homozygous deletions of NPRL2/G21 were detected in 6 tumor biopsies from various locations and with microsatellite instability. This study, together with previously obtained results, indicates that NPRL2 is a multiple tumor suppressor gene.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15374952     DOI: 10.1158/0008-5472.CAN-03-3869

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

Review 1.  Amino acid management in cancer.

Authors:  Zhi-Yang Tsun; Richard Possemato
Journal:  Semin Cell Dev Biol       Date:  2015-08-12       Impact factor: 7.727

2.  Cell signalling: nutrient sensing lost in cancer.

Authors:  Suchithra Menon; Brendan D Manning
Journal:  Nature       Date:  2013-06-27       Impact factor: 49.962

Review 3.  SEA you later alli-GATOR--a dynamic regulator of the TORC1 stress response pathway.

Authors:  Svetlana Dokudovskaya; Michael P Rout
Journal:  J Cell Sci       Date:  2015-05-01       Impact factor: 5.285

4.  Npr2, yeast homolog of the human tumor suppressor NPRL2, is a target of Grr1 required for adaptation to growth on diverse nitrogen sources.

Authors:  Nathalie Spielewoy; Marisela Guaderrama; James A Wohlschlegel; Mabelle Ashe; John R Yates; Curt Wittenberg
Journal:  Eukaryot Cell       Date:  2010-02-12

5.  Relationship between tumor and peripheral blood NPRL2 mRNA levels in patients with colorectal adenoma and colorectal cancer.

Authors:  Ai-yun Liu; Dian-Ggang Liu; Ya-ju Du; Feng-hua Pei; Guang Yang; Bing-rong Liu; Hui-tao Zhang; Xin-hong Wang; Yu-jing Fan; Ying-zhun Chen; Yang Jiang; Jing Chen
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

6.  TUSC4 functions as a tumor suppressor by regulating BRCA1 stability.

Authors:  Yang Peng; Hui Dai; Edward Wang; Curtis Chun-Jen Lin; Wei Mo; Guang Peng; Shiaw-Yih Lin
Journal:  Cancer Res       Date:  2014-12-05       Impact factor: 12.701

Review 7.  Multiple amino acid sensing inputs to mTORC1.

Authors:  Mitsugu Shimobayashi; Michael N Hall
Journal:  Cell Res       Date:  2015-12-11       Impact factor: 25.617

8.  Simultaneous down-regulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer.

Authors:  Vera N Senchenko; Ekaterina A Anedchenko; Tatiana T Kondratieva; George S Krasnov; Alexei A Dmitriev; Veronika I Zabarovska; Tatiana V Pavlova; Vladimir I Kashuba; Michael I Lerman; Eugene R Zabarovsky
Journal:  BMC Cancer       Date:  2010-03-01       Impact factor: 4.430

9.  High mutability of the tumor suppressor genes RASSF1 and RBSP3 (CTDSPL) in cancer.

Authors:  Vladimir I Kashuba; Tatiana V Pavlova; Elvira V Grigorieva; Alexey Kutsenko; Surya Pavan Yenamandra; Jingfeng Li; Fuli Wang; Alexei I Protopopov; Veronika I Zabarovska; Vera Senchenko; Klas Haraldson; Tatiana Eshchenko; Julia Kobliakova; Olga Vorontsova; Igor Kuzmin; Eleonora Braga; Vladimir M Blinov; Lev L Kisselev; Yi-Xin Zeng; Ingemar Ernberg; Michael I Lerman; George Klein; Eugene R Zabarovsky
Journal:  PLoS One       Date:  2009-05-29       Impact factor: 3.240

10.  A genome-wide screen for regulators of TORC1 in response to amino acid starvation reveals a conserved Npr2/3 complex.

Authors:  Taavi K Neklesa; Ronald W Davis
Journal:  PLoS Genet       Date:  2009-06-12       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.